SCN5A mutations in probands with Brugada syndrome were associated with a significantly higher risk of cardiac events compared to those without mutations (HR 2.0; P=0.045).
Cohort (n=415)
Yes
Effect estimate: HR 2.0
p-value: p=0.045
Background: The genotype-phenotype correlation of SCN5A mutations as a predictor of cardiac events in Brugada syndrome remains controversial. We aimed to establish a registry limited to probands, with a long follow-up period, so that the genotype-phenotype correlation of SCN5A mutations in Brugada syndrome can be examined without patient selection bias. Methods: This multicenter registry enrolled 415 probands (n=403; men, 97%; age, 46±14 years) diagnosed with Brugada syndrome whose SCN5A gene was analyzed for mutations. Results: During a mean follow-up period of 72 months, the overall cardiac event rate was 2.5%/y. In comparison with probands without mutations ( SCN5A (–), n=355), probands with SCN5A mutations ( SCN5A (+), n=60) experienced their first cardiac event at a younger age (34 versus 42 years, P =0.013), had a higher positive rate of late potentials (89% versus 73%, P =0.016), exhibited longer P-wave, PQ, and QRS durations, and had a higher rate of cardiac events ( P =0.017 by log-rank). Multivariate analysis indicated that only SCN5A mutation and history of aborted cardiac arrest were significant predictors of cardiac events ( SCN5A (+) versus SCN5A (–): hazard ratio, 2.0 and P =0.045; history of aborted cardiac arrest versus no such history: hazard ratio, 6.5 and P <0.001). Conclusions: Brugada syndrome patients with SCN5A mutations exhibit more conduction abnormalities on ECG and have higher risk for cardiac events.
Yamagata et al. (Sat,) conducted a cohort in Brugada syndrome (n=415). SCN5A mutation vs. No SCN5A mutation was evaluated on Cardiac events (HR 2.0, p=0.045). SCN5A mutations in probands with Brugada syndrome were associated with a significantly higher risk of cardiac events compared to those without mutations (HR 2.0; P=0.045).